Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia?

Trial Profile

Selective Estrogen Receptor Modulators - A Potential Treatment for Psychotic Symptoms of Schizophrenia?

Completed
Phase of Trial: Phase IV

Latest Information Update: 20 Jul 2016

At a glance

  • Drugs Raloxifene (Primary)
  • Indications Psychotic disorders; Schizoaffective disorder; Schizophrenia
  • Focus Therapeutic Use
  • Most Recent Events

    • 20 Jul 2016 According to the results published in the JAMA psychiatry ,Primary endpoint (PANSS score at trial completion (12 weeks)) has not been met.
    • 20 Jul 2016 Results published in the JAMA Psychiatry
    • 29 Jan 2015 Status changed from recruiting to completed, as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top